# QL2107

Source: https://onco.cc/drugs/ql2107/  
OnCo record `ql2107` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

QL2107 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.

## Summary

QL2107 is an investigational agent whose form is not stated in the registry developed by Qilu Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 200mg on day 1 of each 21-day cycle of the study. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06754644 (A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC), in non-small-cell lung cancer. The largest, NCT06754644, plans to enrol 808 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: not stated (registered as a drug or biological on ClinicalTrials.gov)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of QL2107: https://clinicaltrials.gov/search?intr=QL2107
- Sponsor page: https://www.qilu-pharma.com

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- trials: [A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm](https://onco.cc/trials/nct07802821/), [A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07256782/), [A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients](https://onco.cc/trials/nct06911827/), [A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC](https://onco.cc/trials/nct06754644/), [Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07162883/), [QLS5132 Combination Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct07453394/)

---
JSON: https://onco.cc/api/v1/entities/ql2107.json